MA54525A - Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie - Google Patents

Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Info

Publication number
MA54525A
MA54525A MA054525A MA54525A MA54525A MA 54525 A MA54525 A MA 54525A MA 054525 A MA054525 A MA 054525A MA 54525 A MA54525 A MA 54525A MA 54525 A MA54525 A MA 54525A
Authority
MA
Morocco
Prior art keywords
disease
treating
methods
bispecific antibodies
bispecific
Prior art date
Application number
MA054525A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Cornelis Jacob Johannes George Bol
Leonardo Andres Sirulnik
Loo Pieter Fokko Van
Ernesto Isaac Wasserman
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54525A publication Critical patent/MA54525A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054525A 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie MA54525A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18214478 2018-12-20

Publications (1)

Publication Number Publication Date
MA54525A true MA54525A (fr) 2021-10-27

Family

ID=65013454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054525A MA54525A (fr) 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Country Status (7)

Country Link
US (2) US11873338B2 (fr)
EP (1) EP3898685A1 (fr)
JP (2) JP2022521036A (fr)
CN (2) CN113366018A (fr)
MA (1) MA54525A (fr)
TW (1) TWI908715B (fr)
WO (1) WO2020130829A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102361336B1 (ko) * 2013-09-10 2022-02-14 쇼와덴코머티리얼즈가부시끼가이샤 슬러리, 연마액 세트, 연마액, 기체의 연마 방법 및 기체
WO2020130829A1 (fr) 2018-12-20 2020-06-25 Merus N.V. Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
WO2023002390A1 (fr) * 2021-07-20 2023-01-26 Abl Bio Inc. Anticorps anti-cll-1 et leurs utilisations
KR20240155263A (ko) * 2022-02-28 2024-10-28 재스퍼 테라퓨틱스 인코포레이티드 병든 조혈 줄기 세포를 고갈시키기 위한 조성물 및 방법
CN119654163A (zh) * 2022-08-09 2025-03-18 魁尔斯弗生物治疗股份有限公司 与clec12a结合的抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322547A1 (fr) 2003-06-25 2011-05-18 Crucell Holland B.V. Lectin specifique de cellules myeloides
CA2569509C (fr) 2004-06-03 2014-08-12 Novimmune S.A. Anticorps anti-cd3 et leurs methodes d'utilisation
EP2059533B1 (fr) 2006-08-30 2012-11-14 Genentech, Inc. Anticorps multispécifiques
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
EP3851459B1 (fr) 2010-09-21 2024-05-01 Altor BioScience, LLC Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
HRP20181717T1 (hr) 2012-09-27 2018-12-28 Merus N.V. Bispecifična igg protutijela kao aktivatori t stanice
WO2015015373A1 (fr) 2013-08-02 2015-02-05 BSH Bosch und Siemens Hausgeräte GmbH Système de table de cuisson
TW201718647A (zh) * 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
ES2693596T3 (es) * 2015-07-10 2018-12-12 Merus N.V. Anticuerpo que se une a CD3 humano
WO2017167350A1 (fr) * 2016-03-30 2017-10-05 Horst Lindhofer Anticorps multispécifiques destinés à être utilisés pour le traitement d'un néoplasme du tractus urinaire
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US11466094B2 (en) * 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
WO2020130829A1 (fr) 2018-12-20 2020-06-25 Merus N.V. Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Also Published As

Publication number Publication date
US20240262912A1 (en) 2024-08-08
CN113366018A (zh) 2021-09-07
CN114344461A (zh) 2022-04-15
JP2024144441A (ja) 2024-10-11
EP3898685A1 (fr) 2021-10-27
JP2022521036A (ja) 2022-04-05
US11873338B2 (en) 2024-01-16
TWI908715B (zh) 2025-12-21
US12503509B2 (en) 2025-12-23
WO2020130829A1 (fr) 2020-06-25
US20220010013A1 (en) 2022-01-13
TW202034952A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
EP3762015A4 (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP4444349A4 (fr) Anticorps cdh17 et méthodes de traitement du cancer
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EP3790540A4 (fr) Méthodes de traitement et de limitation du developpement de troubles neurologiques liés à une maladie cardiovasculaire
MA54313A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
FR25C1007I1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
EP3716949A4 (fr) Méthodes de traitement d'une maladie auto-immune
EP3920940A4 (fr) Méthodes de prévention et de traitement d'une inflammation et d'une maladie inflammatoire
EP3716875A4 (fr) Appareil et procédé pour le traitement d'une maladie prostatique
EP3976053A4 (fr) Compositions et méthodes de traitement d'une maladie métabolique
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl